Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolMLTXnews
Exchange: NASDAQ·Updated 07:30 PM EDT

MLTX News

News
all
press releases
Healthcare Stocks Ignite: Oncology Pushes, Breakout Battles, and Next Big Growth Catalysts
Healthcare stocks are heating up, and investors have a fresh lineup of catalysts to watch. Pfizer (NYSE:PFE) is pushing its oncology story back into the spotlight, while NeOnc Technologies Holdings (NASDAQ:NTHI) is emerging as a high-volatility biotech to watch as brain-cancer milestones, Abu Dhabi expansion and a battle around key technical levels converge. Avantor (NYSE:AVTR) faces a crucial earnings test that could determine whether its recovery has more room to run, while Eli Lilly and Co (NYSE:LLY) is building on its blockbuster drug franchise with encouraging new pediatric clinical data. Takeda Pharmaceutical (NYSE:TAK) brings global pipeline potential and diversified drug-market exposure to the mix, while MoonLake Immunotherapeutics (NASDAQ:MLTX) is drawing trader attention with active trading putting its next potential catalyst under the microscope.
24-7 Market News
Healthcare Stocks Ignite: Oncology Pushes, Breakout Battles, and Next Big Growth Catalysts
Healthcare stocks are heating up, and investors have a fresh lineup of catalysts to watch. Pfizer (NYSE:PFE) is pushing its oncology story back into the spotlight, while NeOnc Technologies Holdings (NASDAQ:NTHI) is emerging as a high-volatility biotech to watch as brain-cancer milestones, Abu Dhabi expansion and a battle around key technical levels converge. Avantor (NYSE:AVTR) faces a crucial earnings test that could determine whether its recovery has more room to run, while Eli Lilly and Co (NYSE:LLY) is building on its blockbuster drug franchise with encouraging new pediatric clinical data. Takeda Pharmaceutical (NYSE:TAK) brings global pipeline potential and diversified drug-market exposure to the mix, while MoonLake Immunotherapeutics (NASDAQ:MLTX) is drawing trader attention with active trading putting its next potential catalyst under the microscope.
24-7 Market News
More News
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.
Stocktwits
MoonLake's Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cash runway backed through mid-2028.read more...
Benzinga
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
At week 16, 42.1% of patients on Sonelokimab achieved at least a 50% improvement in psoriatic arthritis symptoms, meeting the trial’s primary endpoint.
Stocktwits
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in certain patients with active psoriatic arthritis.
Stocktwits
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.
Stocktwits
MoonLake Immunotherapeutics' CFO Sells 39K Shares
Key PointsThe executive sold 39,120 shares on June 22...
Nasdaq News: Markets
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa...
Yahoo! Finance: News
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
Key PointsIt aims to raise up to $200 million in the offering...
Nasdaq News: Markets

Advertisement|Remove ads.